时间驱动作业成本法建模:乳腺显微血管重建ERAS路径的成本效用
本研究用决策分析模型比较乳腺显微血管重建中ERAS路径与标准治疗的成效益,成本采用时间驱动作业成本法估算,健康状态概率与效用值取自已发表文献,支付方为第三方。结果显示ERAS同时更便宜且更有效,属优势策略;敏感性分析显示当额外成本超过19,336.75美元时ERAS转为不具成本效益。
要点
- ERAS在乳腺显微血管重建中较标准治疗更省钱且更有效,为优势策略。
- 敏感性分析中ERAS额外成本超过19,336.75美元时ICUR超过50,000美元/质量调整生命年。
- 标准治疗需将住院时间从5.96天降至3.36天才具成本效益。
核心结论
- 在乳腺显微血管重建中,ERAS路径较标准治疗总体成本更低且结局更优,属优势策略。
- 尽管ERAS增加药物与人力成本,这些发现仍支持在乳腺显微血管重建中实施ERAS。
研究设计与样本
- 研究为决策分析模型,比较ERAS与标准治疗在乳腺显微血管重建后的临床相关健康状态。
- 概率与效用评分取自已发表文献,采用第三方支付方视角。
- 成本采用时间驱动作业成本法映射与估算,并进行敏感性分析检验结果稳健性。
主要发现
- 汇总5项研究共986例患者的结果生成健康状态概率。
- ERAS被判定为优势策略,即成本更低且效果更好。
- 敏感性分析中,当ERAS额外成本超过19,336.75美元时,增量成本效用比超过50,000美元/质量调整生命年而转为不具成本效益。
- 标准治疗需将住院时间从5.96天缩短至3.36天才具成本效益。
- 蒙特卡洛分析显示在一系列支付意愿值下ERAS均为更具成本效益的选项。
关键数值与推荐
- 成本效益阈值:增量成本效用比>50,000美元/质量调整生命年视为不具成本效益。
- ERAS转为不具成本效益的额外成本界值为>19,336.75美元。
- 标准治疗具成本效益所需住院时间:由5.96天降至3.36天。
临床怎么用
- 可将ERAS作为乳腺显微血管重建的默认路径,因其总体成本更低且结局更优。
- 时间驱动作业成本法可提供细粒度成本估计,适合用于质量改进项目。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Enhanced recovery after surgery (ERAS) programs are being used increasingly in microvascular breast reconstruction. However, it is unclear as to what extent the benefits outweigh the costs. We hypothesized that an ERAS pathway for microvascular breast reconstruction would be cost-effective relative to the standard of care. STUDY DESIGN: A decision-analytic model was made incorporating clinically relevant health states after microvascular breast reconstruction with ERAS vs standard of care. Probabilities and utility scores were abstracted from published sources, and a third-party payer perspective was adopted. Time-driven activity-based costing was used to map and estimate costs attributed to ERAS. Sensitivity analyses were performed to examine the robustness of the results. RESULTS: The results of 5 studies, totaling 986 patients, were pooled to generate health state probabilities. ERAS was found to be dominant, being both less expensive and more effective than standard of care. On sensitivity analysis, ERAS becomes cost-ineffective (incremental cost-utility ratio > $50,000/quality-adjusted life year) at an amount > $19,336.75. Length of stay would have to be reduced from 5.96 days to 3.36 days for standard of care to become cost-effective. Monte-Carlo analysis demonstrated ERAS to be the more cost-effective option across a range of willingness-to-pay values. CONCLUSIONS: Despite the increased medication and personnel costs attributed to ERAS, it is less costly overall and associated with superior outcomes compared with standard of care. These findings lend additional support to the value of ERAS implementation in microvascular breast reconstruction. Time-driven activity-based costing provides granular estimates and are useful in quality-improvement initiatives.
引用
- Mericli AF, McHugh T, Kruse B, et al. Time-Driven Activity-Based Costing to Model Cost Utility of Enhanced Recovery after Surgery Pathways in Microvascular Breast Reconstruction. J Am Coll Surg. 2020. PMID: 32224032. doi:10.1016/j.jamcollsurg.2020.01.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。